Expired CME Article

Malaria Primer for Clinicians in the United States

Authors: Gregory H. Bledsoe, MD, MPH


Though low, the incidence of malaria in the United States is not insignificant and can be the source of infection in febrile travelers returning from endemic areas. Clinicians practicing in the United States must have a basic understanding of the malaria life cycle and its treatments to properly diagnose and treat this potentially fatal disease. Malaria chemotherapy can be broken into clinical classes for easier understanding, and any traveler to a malaria-endemic region should be placed on prophylactic medications. Mosquito bite prevention should be undertaken by all travelers, and methods of deterring mosquito bites should be understood.

Key Points

* In the United States, there are approximately 1,400 cases of malaria reported to the Centers for Disease Control and Prevention every year, most of which are in travelers returning from malaria-endemic regions.

* Clinicians must maintain a high level of suspicion to correctly diagnose malaria.

* An understanding of the Plasmodium life cycle and current treatment protocols are necessary to facilitate proper and timely treatment of patients with malaria. The Centers for Disease Control and Prevention maintain a malaria hotline to assist with malaria treatment.

* All travelers to malaria endemic regions should be placed on appropriate chemoprophylaxis.

* Mosquito bite prevention is still an important component of disease prevention.

This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.


1. Filler S, Causer LM, Newman RD, et al. Malaria surveillance: United States, 2001. MMWR Surveill Summ 2003;52:1–14.
2. Kyriacou DN, Spira AM, Talan DA, et al. Emergency department presentation and misdiagnosis of imported falciparum malaria. Ann Emerg Med 1996;27:696–699.
3. Suh KN, Kain KC, Keystone JS. Malaria. CMAJ 2004;170:1693–1702.
4. Jerrard DA, Broder JS, Hanna JR, et al. Malaria: a rising incidence in the United States. J Emerg Med 2002;23:23–33.
5. Local transmission of Plasmodium vivax malaria: Palm Beach County, Florida, 2003. MMWR Morb Mortal Wkly Rep 2003;52:908–911.
6. Multifocal autochthonous transmission of malaria: Florida, 2003. MMWR Morb Mortal Wkly Rep2004;53:412–413.
7. Layton M, Parise ME, Campbell CC, et al. Mosquito-transmitted malaria in New York City, 1993.Lancet 1995;346:729–731.
8. Local transmission of Plasmodium vivax malaria: Virginia, 2002. MMWR Morb Mortal Wkly Rep2002;51:921–923.
9. Maldonado YA, Nahlen BL, Roberto RR, et al. Transmission of Plasmodium vivax malaria in San Diego County, California, 1986. Am J Trop Med Hyg 1990;42:3–9.
10. Band JD. Malaria, in Emergency Medicine: A Comprehensive Study Guide, JE Tintinalli, GD Kelen, and JS Stapczynski, Editors. 2004, McGraw-Hill: New York. 953–958.
11. Daily JP, Waldron MA. Case records of the Massachusetts General Hospital: weekly clinicopathological exercises: case 22–2003: a 22-year-old man with chills and fever after a stay in South America. N Engl J Med 2003;349:287–295.
12. Svenson JE, Gyorkos TW, MacLean JD. Diagnosis of malaria in the febrile traveler. Am J Trop Med Hyg 1995;53:518–521.
13. Hogh B, Clarke PD, Camus D, et al. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study: Malarone International Study Team. Lancet 2000;356:1888–1894.
14. McKeage K, Scott L. Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria. Drugs 2003;63:597–623.
15. Chiodini PL. Non-microscopic methods for diagnosis of malaria. Lancet 1998;351:80–81.
16. Muehlberger N, Jelinek T, Schlipkoeter U, et al. Effectiveness of chemoprophylaxis and other determinants of malaria in travellers to Kenya. Trop Med Int Health 1998;3:357–363.
17. Malaria, in Control of Communicable Diseases Manual, J. Chin, Editor. 2000, American Public Health Association: Washington, DC.
18. Kain KC, Shanks GD, Keystone JS. Malaria chemoprophylaxis in the age of drug resistance, I: currently recommended drug regimens. Clin Infect Dis 2001;33:226–234.
19. Bradley DJ, Bannister B. Guidelines for malaria prevention in travellers from the United Kingdom for 2001. Commun Dis Public Health 2001;4:84–101.
20. Baird JK, Fryauff DJ, Hoffman SL. Primaquine for prevention of malaria in travelers. Clin Infect Dis2003;37:1659–1667.
21. Reid AJ, Whitty CJ, Ayles HM, et al. Malaria at Christmas: risks of prophylaxis versus risks of malaria. BMJ 1998;317:1506–1508.
22. Arguin P, et al. Malaria, in Health Information for International Travel 2003–2004, PM Arguin, et al, Editors. 2003, US Department of Health and Human Services: Atlanta. 99–116.
23. Carson PE, et al. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science1956;124:484–485.
24. Illinois Department of Corrections Archives Unit, April 2003.
25. Steffen R, Fuchs E, Schildknecht J, et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa. Lancet 1993;341:1299–1303.
26. Lobel HO, Miani M, Eng T, et al. Long-term malaria prophylaxis with weekly mefloquine. Lancet1993;341:848–851.
27. Magill AJ. The prevention of malaria. Prim Care 2002;29:815–842.
28. Pukrittayakamee S, Chantra A, Vanijanonta S, et al. Therapeutic responses to quinine and clindamycin in multidrug-resistant falciparum malaria. Antimicrob Agents Chemother 2000;44:2395–2398.
29. Humar A, Sharma S, Zoutman D, et al. Fatal falciparum malaria in Canadian travellers. CMAJ1997;156:1165–1167.
30. Rosenthal PJ, Petersen C, Geertsma FR, et al. Availability of intravenous quinidine for falciparum malaria. N Engl J Med 1996;335:138.
31. Nosten F, Luxemburger C, ter Kuile FO, et al. Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. J Infect Dis 1994;170:971–977.
32. Bledsoe GH. The West Nile virus: a lesson in emerging infections. Wilderness Environ Med2004;15:113–118.
33. Foster WA, Lutes KI. Tests of ultrasonic emissions on mosquito attraction to hosts in a flight chamber. J Am Mosq Control Assoc 1985;1:199–202.
34. Fradin MS. Mosquitoes and mosquito repellents: a clinician's guide. Ann Intern Med 1998;128:931–940.
35. Fradin MS, Day JF. Comparative efficacy of insect repellents against mosquito bites. N Engl J Med2002;347:13–18.
36. Govere J, Braack LE, Durrheim DN, et al. Repellent effects on Anopheles arabiensis biting humans in Kruger Park, South Africa. Med Vet Entomol 2001;15:287–292.
37. Heal JD, Surgeoner GA, Lindsay LR. Permethrin as a tent treatment for protection against field populations of Aedes mosquitoes. J Am Mosq Control Assoc 1995;11:99–102.
38. Graham K, Mohammad N, Rehman H, et al. Insecticide-treated plastic tarpaulins for control of malaria vectors in refugee camps. Med Vet Entomol 2002;16:404–408.
39. Schreck CE. Permethrin and dimethyl phthalate as tent fabric treatments against Aedes aegypti. J Am Mosq Control Assoc 1991;7:533–535.
40. Lillie TH, Schreck CE, Rahe AJ. Effectiveness of personal protection against mosquitoes in Alaska.J Med Entomol 1988;25:475–478.
41. Sholdt LL, Schreck CE, Qureshi A, et al. Field bioassays of permethrin-treated uniforms and a new extended duration repellent against mosquitoes in Pakistan. J Am Mosq Control Assoc 1988;4:233–236.
42. Bouma MJ, Parvez SD, Nesbit R, et al. Malaria control using permethrin applied to tents of nomadic Afghan refugees in northern Pakistan. Bull World Health Organ 1996;74:413–421.
43. Marchant T, Schellenberg JA, Edgar T, et al. Socially marketed insecticide-treated nets improve malaria and anaemia in pregnancy in southern Tanzania. Trop Med Int Health 2002;7:149–158.
44. Rowland M, Durrani N, Hewitt S, et al. Permethrin-treated chaddars and top-sheets: appropriate technology for protection against malaria in Afghanistan and other complex emergencies. Trans R Soc Trop Med Hyg 1999;93:465–472.
45. Abramowicz M. Advice for Travelers. Treatment Guidelines from The Medical Letter 2004;2:33–40.